Literature DB >> 2541127

Cytomegalovirus and the acquired immunodeficiency syndrome.

A S Tyms1, D L Taylor, J M Parkin.   

Abstract

The acquired immunodeficiency syndrome (AIDS) is complex in nature with one major aetiological factor but with numerous other agents exploiting the immune incompetence. Cytomegaloviruses (CMV) form a little-defined group of viruses which naturally persist in man and respond readily to the relaxation in immune surveillance. A role for CMV and other herpesviruses in potentiating the underlying infection with human immune deficiency virus (HIV) cannot be totally excluded but CMV is well established as a major opportunist in AIDS. They are considered responsible for a range of diseases in AIDS patients including retinitis, gastrointestinal disease, pneumonitis and, less frequently, encephalitis. The pyrophosphate analogue foscarnet (phosphonoformate) and the deoxyguanosine analogue ganciclovir have both been used to treat CMV infections in AIDS patients. Results of uncontrolled studies have indicated efficacy with both drugs but the work with ganciclovir is particularly encouraging. This communication provides a review of CMV infections in AIDS patients with special reference to the experiences to-date in the use of ganciclovir and foscarnet.

Entities:  

Mesh:

Year:  1989        PMID: 2541127     DOI: 10.1093/jac/23.suppl_a.89

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

1.  Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro.

Authors:  R Snoeck; G Andrei; D Schols; J Balzarini; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-12       Impact factor: 3.267

2.  Impaired arterial reactivity following cytomegalovirus infection in the immunosuppressed rat.

Authors:  P H Eerdmans; M C Persoons; S J Debets; H A Struijker Boudier; J F Smits; C A Bruggeman; J G De Mey
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

3.  Generation and application of a monoclonal antibody raised against a recombinant cytomegalovirus-specific polypeptide.

Authors:  G Jahn; H P Harthus; M Bröker; B Borisch; B Platzer; B Plachter
Journal:  Klin Wochenschr       Date:  1990-10-17

4.  Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus.

Authors:  G Andrei; R Snoeck; D Schols; P Goubau; J Desmyter; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-12       Impact factor: 3.267

Review 5.  "The end of innocence" revisited: resistance of herpesviruses to antiviral drugs.

Authors:  A K Field; K K Biron
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

6.  Cytomegalovirus infection- and age-dependent changes in human CD8+ T-cell cytokine expression patterns.

Authors:  Benjamin Faist; Bernhard Fleischer; Marc Jacobsen
Journal:  Clin Vaccine Immunol       Date:  2010-04-28

7.  Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation.

Authors:  R Mañez; S Kusne; M Green; K Abu-Elmagd; W Irish; J Reyes; H Furukawa; A Tzakis; J J Fung; S Todo
Journal:  Transplantation       Date:  1995-04-15       Impact factor: 4.939

8.  Activity of the anti-HIV agent 9-(2-phosphonyl-methoxyethyl)-2,6-diaminopurine against cytomegalovirus in vitro and in vivo.

Authors:  J Neyts; F Stals; C Bruggeman; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-06       Impact factor: 3.267

9.  Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice.

Authors:  J Neyts; H Sobis; R Snoeck; M Vandeputte; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-04       Impact factor: 3.267

10.  Cytomegalovirus infection of the brain in AIDS: a clinicopathological study.

Authors:  U Setinek; E Wondrusch; K Jellinger; A Steuer; M Drlicek; W Grisold; F Lintner
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.